acihexal 250mg
novartis new zealand ltd - aciclovir 250mg - powder for infusion - 250 mg - active: aciclovir 250mg excipient: sodium hydroxide
arrow - metformin 250
actavis new zealand limited - metformin hydrochloride 250mg - coated tablet - 250 mg - active: metformin hydrochloride 250mg excipient: magnesium stearate opadry clear oy-29020 povidone water
ovidrel solution for injection 250 mcg
merck pte. ltd. - choriogonadotropin alfa - injection, solution - 250 mcg - choriogonadotropin alfa 250 mcg
elfonis® 400 mg/250 ml 400 mg/ 250 ml infusion
modern pharmaceutical company serbia - 250 ml glass bottle - infusion - 400 mg/ 250 ml - infections-antibacterial
haluran® 250 ml inhalation
alphamed drug store saudi arabia - 250ml bottle - inhalation - 250 ml - anaesthesia-general anaesthesia
promozio 250/100
sanofi-aventis new zealand limited - atovaquone 250mg; proguanil hydrochloride 100mg - film coated tablet - active: atovaquone 250mg proguanil hydrochloride 100mg excipient: colloidal silicon dioxide hyprolose magnesium stearate microcrystalline cellulose opadry brown 03c86943 poloxamer sodium starch glycolate tolpovidone i 131 - promozio (250mg atovaquone/100mg proguanil hydrochloride) is indicated for: · prophylaxis of plasmodium falciparum malaria in adults · treatment of plasmodium falciparum malaria in adults.
advate
takeda new zealand limited - octocog alfa 250 [iu]; - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.
benefix
pfizer new zealand limited - nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage); nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) - powder for injection with diluent - 250 iu - active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose water for injection sodium chloride water for injection active: nonacog alfa 250 [iu] (actual amount is 275 iu which includes 10% overage) excipient: glycine histidine polysorbate 80 sucrose - for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings.
cefuroxime 250mg
douglas pharmaceuticals limited - cefuroxime sodium 256mg equivalent to 250 mg cefuroxime anhydrous; - powder for injection - 250 mg - active: cefuroxime sodium 256mg equivalent to 250 mg cefuroxime anhydrous
feiba nf
takeda new zealand limited - factor viii inhibitor bypassing fraction 2500 u; ; - powder for injection with diluent - 2500 u - active: factor viii inhibitor bypassing fraction 2500 u excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.